152 related articles for article (PubMed ID: 11179604)
1. SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells.
Moody TW; Chiles J; Casibang M; Moody E; Chan D; Davis TP
Peptides; 2001 Jan; 22(1):109-15. PubMed ID: 11179604
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692.
Iwase K; Evers BM; Hellmich MR; Kim HJ; Higashide S; Gully D; Thompson JC; Townsend CM
Cancer; 1997 May; 79(9):1787-93. PubMed ID: 9128997
[TBL] [Abstract][Full Text] [Related]
3. CAI inhibits the growth of small cell lung cancer cells.
Moody TW; Chiles J; Moody E; Sieczkiewicz GJ; Kohn EC
Lung Cancer; 2003 Mar; 39(3):279-88. PubMed ID: 12609566
[TBL] [Abstract][Full Text] [Related]
4. Indirect inhibitory effect of a neurotensin receptor antagonist on human colon cancer (LoVo) growth.
Iwase K; Evers BM; Hellmich MR; Kim HJ; Higashide S; Gully D; Townsend CM
Surg Oncol; 1996; 5(5-6):245-51. PubMed ID: 9129137
[TBL] [Abstract][Full Text] [Related]
5. Neuromedin B binds with high affinity, elevates cytosolic calcium and stimulates the growth of small-cell lung cancer cell lines.
Moody TW; Staley J; Zia F; Coy DH; Jensen RT
J Pharmacol Exp Ther; 1992 Oct; 263(1):311-7. PubMed ID: 1328611
[TBL] [Abstract][Full Text] [Related]
6. SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.
Moody TW; Chan DC; Mantey SA; Moreno P; Jensen RT
Life Sci; 2014 Mar; 100(1):25-34. PubMed ID: 24496038
[TBL] [Abstract][Full Text] [Related]
7. Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells.
Leyton J; Garcia-Marin L; Jensen RT; Moody TW
Eur J Pharmacol; 2002 May; 442(3):179-86. PubMed ID: 12065070
[TBL] [Abstract][Full Text] [Related]
8. CI-988 inhibits growth of small cell lung cancer cells.
Moody TW; Jensen RT
J Pharmacol Exp Ther; 2001 Dec; 299(3):1154-60. PubMed ID: 11714907
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the effect of SR48692 on inositol monophosphate, cyclic GMP and cyclic AMP responses linked to neurotensin receptor activation in neuronal and non-neuronal cells.
Oury-Donat F; Thurneyssen O; Gonalons N; Forgez P; Gully D; Le Fur G; Soubrie P
Br J Pharmacol; 1995 Sep; 116(2):1899-905. PubMed ID: 8528577
[TBL] [Abstract][Full Text] [Related]
10. Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells.
Zhang Y; Zhu S; Yi L; Liu Y; Cui H
Mol Cell Biochem; 2014 Apr; 389(1-2):1-8. PubMed ID: 24357116
[TBL] [Abstract][Full Text] [Related]
11. Neurotensin elevates cytosolic calcium in small cell lung cancer cells.
Staley J; Fiskum G; Davis TP; Moody TW
Peptides; 1989; 10(6):1217-21. PubMed ID: 2560176
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology and functional properties of NTS2 neurotensin receptors in cerebellar granule cells.
Sarret P; Gendron L; Kilian P; Nguyen HM; Gallo-Payet N; Payet MD; Beaudet A
J Biol Chem; 2002 Sep; 277(39):36233-43. PubMed ID: 12084713
[TBL] [Abstract][Full Text] [Related]
13. Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells.
Moody TW; Leyton J; Garcia-Marin L; Jensen RT
Eur J Pharmacol; 2003 Aug; 474(1):21-9. PubMed ID: 12909192
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.
Nakanishi Y; Mulshine JL; Kasprzyk PG; Natale RB; Maneckjee R; Avis I; Treston AM; Gazdar AF; Minna JD; Cuttitta F
J Clin Invest; 1988 Jul; 82(1):354-9. PubMed ID: 2839551
[TBL] [Abstract][Full Text] [Related]
15. Sigma ligands inhibit the growth of small cell lung cancer cells.
Moody TW; Leyton J; John C
Life Sci; 2000 Apr; 66(20):1979-86. PubMed ID: 10821122
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment with SR48692 has different effects on central neurotensin-induced gastric mucosal defense and inhibition of gastric acid secretion in rats.
Karinch AM; Schmidt GL; Kauffman GL
Brain Res; 1998 Nov; 810(1-2):123-9. PubMed ID: 9813278
[TBL] [Abstract][Full Text] [Related]
17. BW2258U89: a GRP receptor antagonist which inhibits small cell lung cancer growth.
Moody TW; Venugopal R; Zia F; Patierno S; Leban JJ; McDermed J
Life Sci; 1995; 56(7):521-9. PubMed ID: 7869832
[TBL] [Abstract][Full Text] [Related]
18. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.
Labbé-Jullié C; Botto JM; Mas MV; Chabry J; Mazella J; Vincent JP; Gully D; Maffrand JP; Kitabgi P
Mol Pharmacol; 1995 May; 47(5):1050-6. PubMed ID: 7746272
[TBL] [Abstract][Full Text] [Related]
19. BW 1023U90: a new GRP receptor antagonist for small-cell lung cancer cells.
Moody TW; Venugopal R; Hu V; Gozes Y; McDermed J; Leban JJ
Peptides; 1996; 17(8):1337-43. PubMed ID: 8971929
[TBL] [Abstract][Full Text] [Related]
20. The non-peptide neurotensin receptor antagonist SR48692 is not a potent antagonist of neurotensin(8-13) responses of rat substantia nigra neurones in vitro.
Pinnock RD; Woodruff GN
Neurosci Lett; 1994 May; 172(1-2):175-8. PubMed ID: 8084529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
